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IL28B polymorphisms are strongly associated with re-
sponse to treatment for HCV infection. IL28B acts on
interferon-stimulated genes via the JAK-STAT path-
way, which has been implicated in development of
insulin resistance. We investigated whether IL28B
polymorphisms are associated with posttransplant
diabetes mellitus (DM). Consecutive HCV patients
who underwent liver transplantation between 1–1995
and 1–2011 were studied. Genotyping of the poly-
morphism rs12979860 was performed on DNA col-
lected from donors and recipients. Posttransplant DM
was screened for by fasting blood glucoses every
1–3 months. Of 221 included patients, 69 developed
posttransplant DM (31%). Twenty-two patients with
recipient IL28B genotype TT (48%), 25with IL28B geno-
type CT (25%) and 22 with IL28B genotype CC (29%)
developed posttransplant DM. TT genotype was sta-
tistically significantly associated with posttransplant
DM over time (log rank p = 0.012 for TT vs. CT and
p = 0.045 for TT vs. CC). Multivariate Cox regression
analysis correcting for donor age, body mass index,
baseline serumglucose, baseline serumcholesterol, re-
cipient age and treated rejection, showed that recipient
IL28B genotype TTwas independently associatedwith
posttransplant DM (hazard ratio 2.51; 95% confidence
interval 1.17–5.40; p = 0.011). We conclude that the
risk of developing posttransplant DM is significantly
increased in recipients carrying the TT polymorphism
of the IL28B gene.
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Introduction
More than 170 million people are chronically infected with
hepatitis C. It has been hypothesized that the hepatitis
C virus (HCV) might escape from eradication by the im-
mune system by inhibiting interferon (IFN)-a-induced ty-
rosine phosphorylation and activation of STAT1 in hepatic
cells (1), a process mediated by suppressors of cytokine
signaling (SOCS)-1 and SOCS-3 which are important phys-
iological regulators of the immune system (2). Thus, HCV
infection may inhibit the positive feedback loop for the am-
plification of endogenous IFN-a. In addition, a clinical study
of chronic HCV patients showed that SOCS-3 overexpres-
sion was associated with nonresponse to treatment of
HCV with peginterferon-alpha (pegIFN-a; Ref. 3).
SOCSmay not only be implicated in the persistence of HCV
infection, but might also cause insulin resistance through
inhibition of tyrosine phosphorylation of insulin receptor
substrate (IRS) proteins (3,4).
Indeed, chronic HCV infection has been associated with a
high prevalence of insulin resistance, both in the pre- and
posttransplant setting (5,6). In addition, sustained virologi-
cal response (SVR) to antiviral treatment has been shown
to improve insulin sensitivity (7).
It has recently been shown that genetic IL28B polymor-
phisms coding for IFN-k are strongly associated with SVR
to pegIFN-a treatment for chronic HCV infection (8).
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Because IFN-k, in analogy with IFN-a, may act on IFN-
stimulated genes (ISGs) via SOCS and the JAK-STAT path-
way (9), we hypothesized that IL28B polymorphismsmight
also be associated with development of diabetes mellitus
(DM) in HCV patients.
To investigate this hypothesis, we investigated the occur-
rence of posttransplant DM according to IFN-k genotype in
a large cohort of HCV patients during long-term follow-up
after liver transplantation (LT).
Patients and Methods
Participants
Consecutive chronic hepatitis C patients who underwent LT between
January 1, 1995 and January 1, 2011 in the Mayo Clinic in Rochester,
Minnesota, were included.
Patients with a pretransplant diagnosis of DM were excluded
DNA was collected prospectively from all donors and recipients. Data were
obtained according to a standard protocol and development of DM was
screened by fasting blood glucoses every 1–3 months during long-term
follow-up after LT. If there were longer lapses between follow-up visits or
if follow-up data were missing, patients were considered non-DM. DM
was defined as a fasting blood glucose level >126 mg/dL on at least two
occasions (10).
A subset of the patients was treated with IFN-based regimens. Treatment
start and duration of therapy was documented.
The study protocol was approved by the Institutional Review Board of the
Mayo Clinic and was carried out in accordance with institutional guidelines.
All participating patients gave informed consent.
Laboratory testing
Virological (genotype, viral load), biochemical and hematological data were
measured in the certified Mayo Clinic laboratories. A sensitive qualitative
assay was used to detect serum HCV RNA (COBAS Amplicor HCV Test, ver-
sion 2.0 assay; RocheMolecular Systems, Branchburg, NJ, USA) with a sen-
sitivity of 100 IU/mL. Genotypes were assigned using nucleotide primers
specific for a 401 base pair target sequence within the NS5 (nonstructural
protein; Ref. 5) region with sequence information compared with published
HCV-type reference sequences using the FASTA algorithm (Wisconsin Ge-
netics Computer Group, Madison, WI, USA).
DNA extraction and IL28B genotyping
DNA was extracted from stored paraffin-fixed liver tissue blocks using the
QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) assay. Tissue was used
because whole blood was not available. Liver tissue from donors was ob-
tained during the donor recovery procedure or from protocolled liver biop-
sies during follow-up after transplantation. Liver tissue from recipients was
obtained from the explanted liver. Donor and recipient DNA was tested for
the polymorphism rs12979860 using the ABI TaqMan allelic discrimination
kit and the ABI7900HT Sequence Detection System (Applied Biosystems,
Carlsbad, CA, USA). The possible genotypes for this biallelic polymorphism
are: CC, CT and TT, where the CC variant has previously been associated
with good response to pegIFN plus RBV therapy in patients infected with
genotype 1 HCV (8,11).
Statistics
The statistical analyses were performed using SPSS, version 17.0.2 (IBM
Corporation, Somers, NY, USA).
Baseline characteristics were compared using Mann–Whitney, Kruskal–
Wallis and chi-square tests as appropriate. The p values in Table 1 were
corrected for multiple testing, according to the Bonferroni method.
The Kaplan–Meier method was used to estimate the effect of recipient
IL28B genotypes on occurrence of posttransplant DM over time. Univariate
andmultivariate Cox regression analyses were applied to assess risk factors
for the development of posttransplant DM over time.
All of the following factors were evaluated in univariate Cox regression
analysis: Age, gender, donor age, body mass index (BMI) corrected for
the amount of ascites removed during the transplant procedure, glucose,
cholesterol, triglycerides, albumin, bilirubin, international normalized ratio,
aspartate aminotransferase, alanine aminotransferase, creatinine, warm is-
chemia time, cold ischemia time, tacrolimus level, cyclosporine level, pred-
nisone dose, HCV RNA, genotype, rejection.
Subsequently, a multivariate model was built, using variables that were sig-
nificantly associated with development of posttransplant DM in univariate
analysis, with a p < 0.15. The following factors were included in the multi-
variate model, because they were associated with posttransplant DM with
a p < 0.15 (Table 2): recipient IL28B genotype, glucose, cholesterol and
donor age.
Gender, recipient age, BMI and early rejection episodes treated with steroid
boluses were forced into the model because it has been previously shown
in the literature that these factors are associated with DM (12,13). Impor-
tantly, in all models, recipient IL28B genotype was statistically significantly
associated with posttransplant DM.We performed a separate analysis, only
including patients with a diagnosis of DM beyond 4 months of follow-up af-
ter orthotopic LT, to avoid bias of patients with transient DM because of the
initial steroid treatment. To avoid confounding by the effect of exogenous
IFN on occurrence of DM, in the final model patients were censored at the
start of IFN-based treatment.
Logistic regression analysis was used to assess the association of post-
transplant DM, donor and recipient IL28B polymorphism with SVR in pa-
tients who were treated with IFN during follow-up after LT.
Results
Patient characteristics
Between January 1, 1995 and January 1, 2011, 329 LT
were performed for chronic hepatitis C in our center. Donor
and recipient liver tissue was available for IL28B geno-
typing in 289 patients. Genotype at the polymorphic site
rs12979860 on chromosome 19 was suitable for analysis
in 256 patients (89%). Thirty-five patients with a pretrans-
plant diagnosis of DM were excluded.
Development of posttransplant DM
Of the remaining 221 patients, 69 developed posttrans-
plant DM (31%). Baseline characteristics are shown in
Table 1.
During a median follow-up of 5.5 years (interquartile range
[IQR] 1.9–9.0), 22 out of 46 patients with recipient IL28B
genotype TT (48%), 25 out of 99 patients with IL28B geno-
type CT (25%) and 22 out of 76 patients with IL28B geno-
type CC (29%) developed posttransplant DM.
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Table 1: Patient characteristics (a) at the time of transplantation and (b) first month after transplantation
Overall (n = 221) Posttransplant DM (n = 69) No DM (n = 152) p-Value∗
(a) Patient characteristics at the time of transplantation1
Male gender (%) 153 (69) 52 (75) 101 (66) 0.183
Age (years) 52 (46–57) 51 (47–58) 52 (45–56) 0.80
HCV genotype (%) 0.24
1 123 (74) 47 (81) 76 (70)
2 21 (13) 4 (7) 17 (16)
3 17 (10) 5 (9) 12 (11)
4 5 (3) 1 (2) 4 (4)
Recipient IL28B polymorphism (%) 0.021
TT 46 (21) 22 (32) 24 (16)
CC 76 (34) 22 (32) 54 (36)
CT 99 (45) 25 (36) 74 (49)
Donor IL28B polymorphism (%) 0.74
TT 18 (9) 6 (10) 12 (9)
CC 101 (52) 30 (48) 71 (54)
CT 74 (38) 26 (42) 48 (37)
BMI (kg/m2) 27 (24–32) 28 (23–32) 27 (25–32) 0.88
Glucose (mg/dL) 100 (88–115) 103 (90–130) 99 (87–112) 0.141
Cholesterol (mg/dL) 119 (86–148) 108 (74–139) 123 (96–153) 0.030
Triglycerides (mg/dL) 82 (57–119) 78 (55–123) 84 (62–116) 0.39
Albumin (g/dL) 3.1 (2.7–3.4) 3.1 (2.6–3.4) 3.1 (2.8–3.4) 0.47
Bilirubin (mg/dL) 2.9 (1.5–4.7) 2.9 (1.9–5.0) 2.9 (1.5–4.7) 0.45
Aspartate aminotransferase (U/L) 100 (70–149) 104 (71–170) 99 (70–142) 0.55
Alanine aminotransferase (U/L) 69 (45–107) 71 (37–105) 68 (47–108) 0.57
Creatinine (mg/dL) 1.1 (0.9–1.3) 1.1 (1.0–1.6) 1.1 (0.9–1.3) 0.049
Hepatitis C virus ribonucleic acid2 (105 IU/mL)3 3.7 (0.4–15.3) 6.2(0.6–23) 2.3 (0.1–12) 0.27
Donor age (years) 45 (28–55) 46 (33–56) 44 (24–55) 0.188
Warm ischemia (min) 44 (37–61) 46 (40–63) 44 (36–60) 0.61
Cold ischemia (min) 428 (364–504) 434 (379–516) 428 (364–494) 0.40
(b) Patient characteristics in the first month after transplantation1
Mean tacrolimus level first month (ng/mL) 9.0 (7.9–10.7) 7.8 (9.0–10.2) 9.0 (7.9–10.8) 0.45
Tacrolimus versus cyclosporine (%) 204 (94) 64 (93) 140 (95) 0.46
Rejection treated with steroid boluses (%) 8 (4) 1 (1) 7 (5) 0.24
1Continuous variables are expressed as median (interquartile range).
2Pretreatment HCV RNA was available in 52 patients.
3Using the Bonferroni correction for multiple testing, p value of <0.02 was considered statistically significant.
Kaplan–Meier analysis showed that recipient TT genotype
was statistically significantly associated with development
of posttransplant DM over time, the 5-year DM-free sur-
vival being 42.9% (95% confidence interval [CI] 25.7–60.1)
for recipient IL28B genotype TT, 71.7% (95%CI 61.5–81.9)
for genotype CT and 65.9% (95% CI 52.9–78.9) for geno-
type CC (log rank p = 0.045 for TT vs. CC; p = 0.012 for
TT vs. CT and p = 0.59 for CC vs. CT; Figure 1).
In contrast, donor IL28B genotypewas not associatedwith
development of posttransplant DM (log rank p = 0.78 for
TT vs. CC and p = 0.71 for TT vs. CT).
There were no statistically significant differences in fibro-
sis stage at the time of diagnosis of posttransplant DM,
according to recipient IL28B genotype. At the time of di-
agnosis of posttransplant DM, 14 patients with recipient
IL28B genotype TT had Metavir fibrosis stage 0, one had
fibrosis stage 1, six had fibrosis stage 2, one had fibrosis
stage 3 and none had fibrosis stage 4. In comparison, 17
patients with recipient IL28B genotype CT had Metavir fi-
brosis stage 0, six had fibrosis stage 1, one had fibrosis
stage 2, one had fibrosis stage 3 and none had fibrosis
stage 4. In addition, 14 patients with recipient IL28B geno-
type CC had Metavir fibrosis stage 0, four patients had
fibrosis stage 1, three had fibrosis stage 2, none had fibro-
sis stage 3 and one had fibrosis stage 4 (Pearson chi-square
p = 0.24).
The proportions of patients using tacrolimus as primary
immunosuppression were similar for patients who devel-
oped posttransplant DM and those who did not. Sixty-four
(93%) of patients who developed posttransplant DM were
treated with tacrolimus, compared to 140 (95%) of pa-
tients who did not develop posttransplant DM (chi-square
p = 0.46).
Levels of HCV viremia did not vary significantly with recip-
ient IL28B genotype. The median pretransplant viral load
was 14 (IQR 3.1–51) × 105 IU/mL for recipient IL28B geno-
type TT, 3.0 (IQR 0.5–18) × 105 IU/mL for genotype CC
and 1.2 (IQR 0.3–10) × 105 IU/mL for genotype CT (overall
Kruskal–Wallis p = 0.50 and Mann–Whitney p = 0.30 for
TT vs. CC/CT).
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Figure 1: Kaplan–Meier
curve showing the di-
abetes mellitus-free sur-
vival according to recipi-
ent IL28B genotype.
Antiviral treatment
A total of 93 patients received antiviral therapy for recur-
rent hepatitis C during follow-up. This antiviral treatment
was started at a median of 1.6 years (IQR 0.8–3.3) af-
ter transplantation. The median duration of treatment was
44 weeks (IQR 23–54) and 39 patients (42%) achieved
SVR.
Eighteen out of 31 patients (58%) with recipient IL28B
genotype CC achieved SVR, 18 out of 38 patients (47%)
with recipient IL28B genotype CT achieved SVR and 3 out
of 24 patients (13%) with recipient IL28B genotype TT
achieved SVR (OR 0.10; 95% CI 0.03–0.42) for TT versus
CC and (OR 0.65; 95% CI 0.25–1.69) for CT vs. CC; p =
0.006. As described previously (14), donor IL28B polymor-
phism was also a predictor of SVR: 24 out of 43 patients
(56%) with donor IL28B genotype CC achieved SVR, 13
out of 37 patients (35%) with donor IL28B genotype CT
achieved SVR and 1 out of 7 patients (14%) with donor
IL28B genotype TT achieved SVR (OR 0.13; 95% CI 0.02–
1.19) for TT versus CC (OR 0.43; 95% CI 0.17–1.06) for
CT versus CC; overall p = 0.061 and TT versus CT/CC
(p = 0.002). Pretreatment DM was not associated with
SVR (OR 1.18; 95% CI 0.51–2.75; p = 0.72) in our cohort.
Predictors of DM
Multivariate Cox regression analysis adjusting for gender,
age, BMI (corrected for the amount of ascites removed
during the transplant procedure), baseline serum glucose,
baseline serum cholesterol, donor age and early rejection
treated with steroid boluses showed that recipient IL28B
genotype TT was independently associated with develop-
ment of posttransplant DM (hazard ratio [HR] 2.51; 95%
CI 1.17–5.40; p = 0.011). In this analysis, which starts at 1
month after transplantation, patients were censored at the
start of IFN-based treatment (Table 2).
We performed a separate analysis, only including patients
with a diagnosis of DM beyond 4 months of follow-up after
LT, to avoid bias of patients with transient DM because of
the initial steroid treatment (15).
Six patients with recipient IL28B genotype TT, 13 patients
with genotype CT and nine patients with genotype CC
developed posttransplant DM within the first 4 months
after transplantation. In this analysis, the results for recip-
ient IL28B genotype remained essentially unchanged (HR
1.86; 95% CI 0.93–3.72; p = 0.017 for recipient TT vs. CC;
Table 2).
Graft survival
To verify that differences in time at risk are not responsi-
ble for the association we found between recipient IL28B
genotype and development of posttransplant DM, we
compared graft survival for the different recipient IL28B
genotypes.
Indeed, there was no difference in overall graft survival
according to recipient IL28B polymorphism.
Ten patients (4.5%) with recipient IL28B CC polymorphism
experienced graft loss, 16 patients (7.2%) with recipi-
ent IL28B CT polymorphism experienced graft loss and
12 patients (5.4%) with recipient IL28B TT polymorphism
740 American Journal of Transplantation 2012; 12: 737–744
IL28B Polymorphism and Posttransplant DM
Ta
b
le
2:
U
ni
va
ria
te
an
d
m
ul
tiv
ar
ia
te
C
ox
re
gr
es
si
on
an
al
ys
es
,e
va
lu
at
in
g
ris
k
fa
ct
or
s
fo
r
po
st
tr
an
sp
la
nt
di
ab
et
es
m
el
lit
us
O
ve
ra
ll
m
ul
tiv
ar
ia
te
C
ox
M
ul
tiv
ar
ia
te
C
ox
re
gr
es
si
on
st
ar
tin
g
at
re
gr
es
si
on
2
ce
ns
or
in
g
U
ni
va
ria
te
C
ox
O
ve
ra
ll
m
ul
tiv
ar
ia
te
4
m
on
th
s
af
te
r
pa
tie
nt
s
at
st
ar
t
of
re
gr
es
si
on
an
al
ys
is
:
C
ox
re
gr
es
si
on
2
:
tr
an
sp
la
nt
at
io
n:
IF
N
-b
as
ed
tr
ea
tm
en
t:
H
R
(9
5%
C
I)
p-
Va
lu
e
H
R
(9
5%
C
I)
p-
Va
lu
e
H
R
(9
5%
C
I)
p-
Va
lu
e
H
R
(9
5%
C
I)
p-
Va
lu
e
M
al
e
ge
nd
er
1.
40
(0
.8
0–
2.
45
)
0.
25
1.
39
(0
.7
5–
2.
86
)
0.
29
1.
53
(0
.7
9–
2.
96
)
0.
21
1.
82
(0
.8
5–
3.
87
)
0.
12
2
H
C
V
ge
no
ty
pe
1
1
(r
ef
)
0.
35
2
0.
42
(0
.1
5 –
1.
17
)
3
0.
76
(0
.3
0 –
1.
92
)
4
0.
50
(0
.0
7 –
3.
62
)
R
ec
ip
ie
nt
IL
28
B
po
ly
m
or
ph
is
m
C
C
1
(r
ef
)
0.
03
7
1
(r
ef
)
0.
01
8
1
(r
ef
)
0.
01
7
1
(r
ef
)
0.
01
1
TT
1.
78
(0
.9
7 –
3.
26
)
2.
03
(1
.0
4–
3.
96
)
1.
86
(0
.9
3–
3.
72
)
2.
51
(1
.1
7–
5.
40
)
C
T
0.
85
(0
.4
8 –
1.
52
)
0.
82
(0
.4
4–
1.
56
)
0.
68
(0
.3
5–
1.
33
)
0.
87
(0
.4
1–
1.
84
)
D
on
or
IL
28
B
po
ly
m
or
ph
is
m
C
C
1
(r
ef
)
0.
95
TT
1.
12
(0
.4
7 –
2.
70
)
C
T
0.
98
(0
.5
7 –
1.
67
)
A
ge
(y
ea
rs
)
1.
01
(0
.9
8 –
1.
04
)
0.
56
1.
01
(0
.9
8–
1.
04
)
0.
51
1.
01
(0
.9
8–
1.
04
)
0.
62
1.
02
(0
.9
8–
1.
06
)
0.
30
B
M
I(
kg
/m
2
)
1.
00
(0
.9
6–
1.
04
)
0.
90
1.
01
(0
.9
6–
1.
06
)
0.
76
1.
00
(0
.9
6–
1.
06
)
0.
79
1.
03
(0
.9
7–
1.
08
)
0.
35
G
lu
co
se
(m
g/
dL
)
1.
00
(1
.0
0 –
1.
01
)
0.
13
4
1.
00
(1
.0
0–
1.
01
)
0.
42
1.
00
(1
.0
0–
1.
01
)
0.
20
1.
00
(0
.9
9–
1.
01
)
0.
73
C
ho
le
st
er
ol
(m
g/
dL
)
0.
99
(0
.9
9 –
1.
00
)
0.
02
8
0.
99
(0
.9
9–
1.
00
)
0.
06
0
0.
99
(0
.9
9–
1.
00
)
0.
06
7
1.
00
(0
.9
9–
1.
00
)
0.
17
2
Tr
ig
lic
er
id
es
(m
g/
dL
)
1.
00
(1
.0
0 –
1.
00
)
0.
88
A
lb
um
in
,g
/d
L
0.
92
(0
.6
0 –
1.
41
)
0.
70
B
ili
ru
bi
n
(m
g/
dL
)
0.
99
(0
.9
7 –
1.
02
)
0.
54
G
am
m
a
G
T
(U
/L
)
1.
00
(1
.0
0 –
1.
00
)
0.
72
A
sp
ar
ta
te
am
in
ot
ra
ns
fe
ra
se
(U
/L
)
1.
00
(1
.0
0 –
1.
00
)
0.
75
A
la
ni
ne
am
in
ot
ra
ns
fe
ra
se
,U
/L
1.
00
(1
.0
0 –
1.
00
)
0.
65
C
re
at
in
in
e
(m
g/
dL
)
1.
06
(0
.8
2 –
1.
37
)
0.
66
H
ep
at
iti
s
C
vi
ru
s
rib
on
uc
le
ic
ac
id
(1
05
IU
/m
L)
1.
00
(1
.0
0–
1.
00
)
0.
18
6
D
on
or
ag
e
(y
ea
rs
)
1.
02
(1
.0
0–
1.
03
)
0.
03
5
1.
01
(1
.0
0–
1.
03
)
0.
17
6
1.
01
(1
.0
0–
1.
03
)
0.
14
8
1.
01
(0
.9
9–
1.
03
)
0.
24
W
ar
m
is
ch
em
ia
(m
in
)
1.
00
(0
.9
9 –
1.
02
)
0.
68
C
ol
d
is
ch
em
ia
(m
in
)
1.
00
(1
.0
0 –
1.
00
)
0.
66
M
ea
n
ta
cr
ol
im
us
le
ve
lfi
rs
t
m
on
th
(n
g/
m
L)
1
0.
90
(0
.7
8–
1.
04
)
0.
15
2
M
ea
n
pr
ed
ni
so
ne
do
se
fir
st
m
on
th
(m
g/
da
y)
1
1.
00
(0
.9
9–
1.
01
)
0.
57
Ta
cr
ol
im
us
ve
rs
us
cy
cl
os
po
rin
e
(%
)1
0.
88
(0
.3
5–
2.
19
)
0.
78
R
ej
ec
tio
n
tr
ea
te
d
w
ith
st
er
oi
d
bo
lu
se
s
(%
)1
0.
37
(0
.0
5–
2.
65
)
0.
32
0.
57
(0
.0
8–
4.
27
)
0.
59
0.
70
(0
.0
9–
5.
22
)
0.
73
0.
80
(0
.1
1–
5.
98
)
0.
83
1
Fo
r
th
es
e
va
ria
bl
es
,t
he
un
iv
ar
ia
te
C
ox
re
gr
es
si
on
an
al
ys
is
st
ar
ts
at
1
m
on
th
af
te
r
tr
an
sp
la
nt
at
io
n.
2
B
ec
au
se
re
je
ct
io
n
tr
ea
te
d
w
ith
st
er
oi
d
bo
lu
se
s
is
in
cl
ud
ed
as
a
va
ria
bl
e
in
th
e
m
ul
tiv
ar
ia
te
an
al
ys
is
,t
hi
s
m
ul
tiv
ar
ia
te
C
ox
re
gr
es
si
on
an
al
ys
is
st
ar
ts
at
1
m
on
th
af
te
r
tr
an
sp
la
nt
at
io
n.
American Journal of Transplantation 2012; 12: 737–744 741
Veldt et al.
experienced graft loss during follow-up (Pearson chi-square
p = 0.174). Mean graft survival was 5.9 years (IQR 2.2–
9.0) for patients with recipient IL28B polymorphism CC,
4.7 years (IQR 1.7–9.0) for patients with recipient IL28B
polymorphism CT and 5.5 years (IQR 23–9.0) for patients
with recipient IL28B polymorphism TT (Kruskal–Wallis
p = 0.58).
Discussion
The most important result of this study is the novel ob-
servation that IL28B polymorphisms are strongly associ-
ated with the development of DM during following LT.
Specifically, recipient IL28B TT genotype is associated
with a more than twofold increase in relative risk for post-
transplant DM. This observation has potentially important
implications.
The fact that only recipient and not donor IL28B polymor-
phisms are associated with development of DM, suggests
either of two possibilities: a role for antigen presenting
cells and immune effector cells, rather than primary hepa-
tocytes in this process, or that the reduced insulin sensitiv-
ity in HCV is not solely related to the hepatocytes. This is
interesting because one of the most important features of
insulin resistance in non-HCV liver cirrhosis lies within the
liver itself, where cirrhosis causes impaired suppression of
hepatic glucose production (16).
We hypothesize that similarities in downstream signaling
of the IFN-aand the IFN-kreceptor might be responsible for
the association between IL28B polymorphisms and devel-
opment of DM in chronic HCV-infected patients. Both IFN-k
and IFN-a act on ISGs via SOCS (9). It has already been
suggested that SOCS may not only be implicated in the
persistence of HCV infection, but might also cause insulin
resistance through inhibition of tyrosine phosphorylation
of IRS proteins (3,4).
It is important to consider whether the observed associ-
ation of recipient IL28B TT genotype and the increased
risk of development of posttransplant DM is simply a re-
flection of the lower frequency of SVR seen among pa-
tients with the TT genotype. Although the mechanisms for
HCV-associated insulin resistance are not fully understood,
the HCV core protein downregulates IRS 1 and 2, promot-
ing insulin resistance (17). In addition, eradication of HCV
has been convincingly shown to improve insulin sensitiv-
ity.When compared to baseline (pretreatment), HOMA2-IR
values fall by a mean of over 2 among patients with com-
plete virological response, compared to increases of 0.2
in HOMA2-IR in nonresponders (18). Several observations
in this study strongly suggest, however, that response to
antiviral therapy, and thus effects of HCV on SOCS and IRS
signaling, was not the basis of recipient IL28B genotype
and development of posttransplant DM. Most importantly,
the HR for recipient IL28B genotype TT for development of
posttransplant DMwas the same if patientswere censored
at the start of IFN-based treatment. In addition, levels of
HCV viremia did not vary significantly with IL28B geno-
type and fibrosis stage at the time of diagnosis of DM was
similar between the different groups.
The fact that recipient TT IL28B genotype is associated
with DM in our study raises some interesting questions
about the possible mechanism by which IFN responsive-
ness varies with IL28B genotype.
IFN-k-3, the product of IL28B, is considered to be a proin-
flammatory cytokine with antiviral properties. The exact
role of IL28B single nucleotide polymorphisms (SNPs) in
the biology of IFN-k-3 remains unknown: There are con-
flicting data regarding a possible association between the
favorable SNPs and expression of IL28B mRNA either in
peripheral blood mononuclear cells (PBMC) or liver tissue
(19–21), and one report failed to demonstrate a more po-
tent antiviral activity (22). However, studies have consis-
tently showed that the unfavorable genotypes (CT and TT
for rs12979860 SNP, and GG and TG for rs8099917) are
associated with an increased expression of ISGs (21–24).
The SOCS family stands out as one of the many ISGs as-
sociated with failed viral eradication (25,26). Remarkably,
SOCS-3 and SOCS-7 have been implicated as causing in-
sulin resistance in the setting of hepatitis C (17,27,28).
It has been described that HCV can induce both SOCS-1
and SOCS-3—either directly through the core protein or
indirectly through tumor necrosis factor alpha/interleukin
6 induction–which impairs signaling of the insulin recep-
tor pathway and causes insulin resistance (17,27,29). Irre-
spective of the mechanistic consequences of these SNPs
in IFN-k-3 biology, a possible upregulation of SOCS in pa-
tientswith CT/TT genotypes could explain the link between
IL28B polymorphisms and the development of DM.
As insulin induces expression of SOCS-3 and SOCS-3 is
known to inhibit IFN signaling (3,4), induction of SOCS-3 by
insulin could contribute to the inhibition of IFN-a signaling
and lower SVR rate associated with IL28B TT genotype.
Functional studies of variability of SOCS-3 signaling and
insulin receptor activity with IL28B genotypes would be
needed to test this hypothesis.
Given that the increased risk for developing insulin resis-
tance and T2DM in hepatitis C is reversed after viral erad-
ication, current findings pose a double benefit for HCV
patients from the metabolic point of view. The inherent
reduced risk for DM in all viremic patients with the CC/CT
genotype, and a further decrease in risk after achieving
viral eradication with antiviral therapy.
Our findings raise some practical considerations. In the
nontransplant setting, DM has been shown to be a risk
factor for development of hepatocellular carcinoma in pa-
tients with HCV (30) and liver transplant patients with HCV
have been shown to have an increased risk of liver graft
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fibrosis (31). As treatment with insulin sensitizing medi-
cations might improve the outcome of HCV patients with
insulin resistance, consideration might be given to screen-
ing for insulin resistance in patients with the IL28B TT
genotype.
Although the mechanisms through which IL28B polymor-
phisms influence insulin sensitivity remain hypothetical as
long as the exact molecular pathways have not been identi-
fied, we believe that our observations may open important
new directions for future research on insulin resistance and
chronic HCV infection. The fact that we studied a large co-
hort of well-characterized patients with a long-term follow-
up, supports the validity of our observations.
Conclusion
The risk of developing posttransplant DM is significantly
increased in recipients carrying the TT polymorphism of
the IL28B gene.
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